initi buy target price
livzon pharma livzon one china lead specialti drug manufactur
enviabl track record strateg transform tradit chines
medicin chemic drug see new growth fuell innov given
acceler clinic progress in-hous augur well launch
blockbust high expect busi develop
cash hand factor recent approv ilaprazol inject
project ep correspond
pe respect target price base
peer-averag pe ep initi coverag buy
ilaprazol new approv drive growth near term
follow ilaprazol inject best-in-class ppi approv januari see
potenti market tablet inject
put revenu compound-annual-growth-rate given oral tablet yoy
revenu growth like acceler entri
nrdl inject formul domin share ppi market
well-establish sale network revenu compound-annual-growth-rate
driver identifi leuprorelin microspher ngf api
shenqi fuzheng remain cash cow pa view
 clinic trial acceler debut expect
see rapid sequenc launch start mab microspher
phase mab complet soon follow phase ii via
orphan drug track liver cancer new drug applic perjeta me-too drug
mab phase complet phase trial rhcg
expect microspher pipelin expect debut
leuprorelin triptorelin aripiprazol
busi develop window license-in
expect livzon join rank top-tier innov drug manufactur
oversea busi develop spur ich polici prompt
accept cfda earli phase clinic data us eu japan
clinic strength sophist channel cash hand
risk view
tender-pric cut delay new launch unqualifi clinic result
huatai financi hold hong kong limit abbrevi huatai hk throughout report
pleas refer end page analyst certif requir disclosur
livzon pharma hk equiti china carebuy tp price price hkd /- cap average daili val price rang pricerel hsi rh hkd ye dec profit dilut ebitda yield cash-flow yield livzon pharma hk
continu ramp-up chemic drug
ilaprazol anticip combin peak sale
in-hous blockbust spring start
oversea bd strong prospect expand innov landscap
initi coverag buy target price
chemic prepar major growth engin
ilaprazol new drive forc spur inject formul
ivf drug famili livzon domest market leader
ngf expect moder growth success re-entri guangdong
api segment continu upward trajectori
ivd precision-medicin ecosystem shape
 bullish mab microspher platform
complet phase us expect soon
lead runner perjeta me-too
potenti blockbust way
tnf- catch first armi
aripiprazol microspher new star schizophrenia market
hormone-rel drug cover full spectrum long-act drug
financi forecast valuat
growth predict ep compound-annual-growth-rate
initi buy target price
risk view
list abbrevi use report
continu ramp-up chemic drug
past five year seen livzon show less depend tcm
inject eg shenqi fuzheng chemic drug becom domin gross
profit revenu lead product fuell eg ilaprazol
leuprorelin microspher saw yoy revenu growth anticip
trend continu includ engag high-end drug
livzon revenu segment
api intermedi
diagnost reagent equip
livzon gross profit segment
api intermedi
diagnost reagent equip
ilaprazol anticip combin peak sale
view ilaprazol inject approv januari boost chemic sector
given strong growth oral tablet yoy like acceler
entri onto nrdl inject mainstream formul
domin share share ppi market well-establish
distribut network strong brand power feel optimist ilaprazol rapid
growth reach peak sale next five year oral
inject given superior clinic efficaci versu ppi peer
ilaprazol revenu growth rate
livzon adjust key product nrdl
radio-chemo therapi lung gastric cancer
n-hexan poison traumat optic neuropathi
in-hous blockbust spring start
compani focus two innov platform mab target therapi
microspher sustain releas product develop
learn recent field trip clinic progress move forward faster
expect three high-potenti mab expect appli nda
name phase complet shortli us phase assum
first perjeta me-too drug china tnf- phase ii/iii microspher
pipelin featur leuprorelin triptorelin aripiprazol
progress smoothli expect make debut
livzon expect success releas in-hous
oversea bd strong prospect expand innov landscap
sinc china enter ich allianc june cdfa begun accept early-
phase clinic data us eu japan becom flexibl oversea
license-in/out believ livzon one first beneficiari liber
given lead talent disciplin pipelin develop professor fu
daotian clinic trial professor liu changdong dai weim strong
sophist sale network staff around cash hand
support high-qual license-in
lead drug supplier cash hand
strong confid livzon organ growth project ep
compound-annual-growth-rate rmb basi ep aris
approv ilaprazol inject yoy increas combin sale
sustain rapid growth revenu leuprorelin microspher yoy ngf
yoy bulk medicin yoy shenqi fuzheng maintain steadi profit
view manag assert acceler grassroot penetr good
prospect launch high-margin soft bag
livzon revenu net profit
acquir invest
cynvenio
abycet enter
product
inject
mab
readi
initi coverag buy target price
initi coverag livzon buy rate target price impli
upsid base pe dilut ep target pe
multipl deriv h-share peer averag pe trend valu
recoveri a- h-share healthcar sector clear prefer
among southbound investor lead h-share compani innov pipelin
note index a- h-share list compani market-cap weight
note calcul use huatai ep estim data februari close
chemic prepar major growth engin
chemic drug becom livzon major growth driver account total
revenu net profit anticip trend continu project
ep compound-annual-growth-rate
livzon revenu segment
api
reagent
livzon gross profit segment
api intermedi
reagent
lead product fuell includ
ilaprazol assum sale compound-annual-growth-rate driven
oral tablet entri onto nrdl inject approv januari
leuprorelin microspher see achiev sale compound-annual-growth-rate
 given lead posit well-establish channel cover
in-vitro fertil ivf center
ngf anticip sale compound-annual-growth-rate
livzon key product current portfolio
tender recoveri guangdong
revenu
ilaprazol new drive forc spur inject formul
regard ilaprazol livzon rise star expect achiev
revenu compound-annual-growth-rate reach combin peak sale tablet
inject next five year given
oral tablet enter nrdl versu previous cover
inject receiv nda approv januari expect inject revenu
time oral tablet inject take ppi market
market share
superior clinic efficaci especi case patient lack
ilaprazol revenu growth
proton pump inhibitor ppi first-lin drug gastric ulcer treatment pdb
databas indic estim domest ppi market calcul
time sampl hospit sale translat low-single-digit annual
ppi market revenu growth
expect exclus patent livzon drug ilaprazol continu see
market expans given favor clinic efficaci among patient exhibit
enzym mutat china popul oral tablet entri onto
nrdl launch inject expect rapid growth sinc
benefit higher price domin share ppi market
ppi comparison product china market
inject market estim time peak sale size
oral formul market given higher unit price inject time
tablet prefer clinic use surgeri hospit
mainstream ppi drug china market
oral categori inject approv jan
note averag tender price calcul averag
ppi inject domin formul
leuprorelin microspher solid growth clinic prefer
estim revenu compound-annual-growth-rate leuprorelin microspher base
strong volum growth yoy lack competit two
domest supplier market well extra space import substitut around
half market space indic extens eg larger penetr cpp
leuprorelin microspher inject
endometriosi children precoci puberti cpp
livzon leuprorelin microspher revenu growth
leuprorelin microspher gain signific popular recognit sinc
introduc takeda mostli owe sustained-releas natur
optim patient experi daili inject monthli inject sinc
livzon lead import substitut increas market share
momentum seem like continu given lower tender price
lower enanton strong sale channel portfolio suppli hospit
ivf center
leuprorelin microspher product domest market
china
provinc
note price deriv averag tender price jiangsu shanghai jilin guizhou hubei guangdong
also see potenti growth livzon leuprorelin microspher indic extens
eg cpp area product took share cpp drug market
howev see market potenti consid broad patient pool
china moder drug penetr rate averag
annual cost per patient
ivf drug famili livzon domest market leader
ivf drug market sustain annual sale growth yoy past
five year versu yoy growth averag overal chemic drug sector among
divers rang varieti follicle-stimul hormon fsh relin-typ drug eg
goserelin leuprorelin triptorelin domin market market share
ivf drug market landscap china
livzon enter assist reproduct field earli becom
domest leader cover four key product throughout full ivf treatment cycl
compani persist upgrad pipelin eg rhcg high-pur
menotrophin three kind relin-drug progress anticip
sale compound-annual-growth-rate given grow trend coupl second child
babi boom expect year pig grow preval work-
livzon ivf drug revenu growth estim
china number birth year
number infant mn
first year univer two-child
polici infant born
second child
nation bureau statist huatai hk research
livzon product cover full ivf treatment cycl
livzon key ivf product fsh menotropin hcg
fsh livzon urinari fsh produc china expect product
maintain steadi growth yoy annual next three year base
recombin product low base partli attribut anim sign
prefer chines zodiac
fsh product domest market
note averag tender price calcul use averag price one cours usual last week around per day
menotropin livzon stand among domest manufactur
market share expect maintain lead posit thank
network advantag deliv steadi growth around yoy annual
also livzon receiv ind approv high-pur
menotrophin market fer current player expect
drug launch achiev fast substitut lower price
menotropin product domest market
note averag tender price calcul use averag price menotrophin one cours usual last three week per day ad
everi seven day start second week highli purifi one cours usual take seven day per day
hcg livzon rhcg track phase expect launch
estim market potenti annual manag guid
would price time price hcg potenti grab
market share livzon hcg product merck
hcg product domest market
note averag tender price calcul averag hcg one cours usual last week inject everi day
ngf expect moder growth success re-entri guangdong
livzon neuro-restor drug ngf achiev sale revenu
expect revenu compound-annual-growth-rate given recoveri previously-
lost bid eg guangdong ngf earli stage develop
show clinic advantag facilit nerv growth low toxic versu peer neuro-
restor drug livzon strong direct-sal team
ngf revenu growth
ngf still earli stage product life continu expand market share
increas compet product experienc
declin market share believ ngf continu captur market share
compet product strictli restrict use adjuv drug
limit nrdl work injury-rel treatment
glycosid
revenu ngf
revenu neuro restor drug
growth ngf rh
growth neuro restor drug rh
neuro restor drug product china market
sale stagnat ac
upstream ngf perform well
celer year
cattl encephalon glycosid ignotin dysfunct gansu
advanc stage cerebr ischemia henan
neurologist diagnosi prescript jilin expens drug
livzon realiz rapid sale expans sinc launch ngf captur
market share momentum falter due fail tender
bid two vital provinc guangdong fujian howev see sustain moder
growth yoy given livzon re-entri guangdong market
competit edg livzon strong direct-sal network
lose bid guangdong
ngf product china market
total revenu yoy growth expect
remain cash cow contribut steadi profit next three year see
upsid downsid effect neg side expect stringent restrict
tcm inject nrdl limit patient undergo radiotherapy/
chemotherapi lung gastric cancer posit side expect
acceler grassroot penetr thank recruit sale staff
non-pvc soft bag launch price least doubl
current price improv gross margin consider
shenqi fuzheng inject revenu growth
shenqi fuzheng total revenu
shenqi fuzheng net profit
note key chemic drug fsh leuprorelin ngf ilaprazol
note key chemic drug fsh leuprorelin ngf ilaprazol
shenqi fuzheng remain safe cost-effect choic see achiev growth
exceed industri averag contribut stabl profit base
limit grassroot clinic institut versu peer limit hospit
lower high-margin soft bag expect launch
anti-canc tcm inject revenu china
lung gastric cancer
intermedi advanc cancer
intermedi advanc cancer
intermedi advanc cancer
intermedi advanc cancer
intermedi advanc cancer
note lentinan inject limit prdl limit yet enter nrdl
intermedi
api segment continu upward trajectori
see clear uptrend livzon align api busi facilit
synerg realloc strateg inclin high-margin product revenu
margin experienc signific improv gross margin
versu revenu growth yoy versu
anticip sale revenu growth yoy continu margin increas
api segment revenu growth
subsidiari turn around becam quit profit averag revenu
growth yoy net profit growth yoy expect see zhuhai livzon
hecheng realiz improv integr api depart
api segment brilliant perform subsidiari
biochem polypeptid api
api intermedi product
antibiot api intermedi
inclin toward high-margin api varieti growth anticip
huadong purchas acarbos livzon api sale
focu high-margin product macrolid
api segment revenu key product
addit livzon continu explor oversea api market exampl
mycophenol acid lovastatin mevastatin livzon pass five fda
on-sit inspect receiv intern certif expect expans
momentum busi remain strong
livzon drug master file fda dmf till dec
ivd precision-medicin ecosystem shape
despit effort earli phase develop livzon strive establish
full ecosystem precis medicin includ tradit ivd eg elisa
inflamm infect livzon diagnost earli diagnosi tumor ctc ctdna
livzon cynvenio diagnost gene detect livzon gene target therapi
livzon mileston precis medicin
livzon diagnost current contribut biggest share profit ivd segment
addit steadi growth agent busi number self-develop
product product develop oversea cooper expect launch
success estim sector deliv revenu growth annual
diagnost reagent equip process
project
project
project
diagnost reagent equip revenu growth
 bullish mab microspher platform
livzon special focu target therapi mab drug long-act
potenti blockbust area oncolog auto-immunolog central nervou
driven acceler clinic progress increas invest project
overal revenu seri new launch expect begin
strateg transform anticip specialti gener
antibodi technolog target therapi
 expens annual cost percentag revenu
revenu rh
monoclon antibodi mab trendsett biolog target therapi six top
global best-sel mab livzon mabpharm establish
boast lead talent segment professor fu daotian liu changdong
dai weim strateg pipelin includ three target attract
widespread attent healthcar industri ie tnf- potenti
new target eg rankl livzon break rank
top-tier mab player china
livzon mab clinic stage sale estim
firm develop
recent field trip observ clinic trial achiev faster-than-
expect progress phase mab expect complet soon
us like nda phase ii via orphan drug track liver cancer anti-
mab perjeta me-too drug mab phase i/iii anti-tnf-
mab formul phase ii/ trial phase trial rhcg expect
complet
complet phase us expect soon
global level new star immune-oncolog i/o mab
particularli term combo-strategi i/o studi world-wide june
lead product ie keytruda opdivo achiev robust growth
expect achiev sale exceed annual evaluatepharma
china drug yet introduc howev opdivo submit nda
nsclc novemb local player speed effort gain first-mov
advantag eg innov nda treatment chl orphan diseas hengrui like
submit nda liver cancer treatment livzon quickli catch
phase endpoint high probabl submit nda
global sale mab
pancreat hepat
head neck uveal
stomach
mab clinic trial china
advanc recurr tumor
note indic drug nda
yet on-going
lead runner perjeta me-too
global stage roch achiev enviabl success herceptin
extend mab famili perjeta domain-ii
yoy kadcyla deal drug toler
china crowd pipelin area herceptin clinic
trial livzon focus perjeta me-too drug see peak
sale consid favor competit environ three compani
approv ind potenti combo-us herceptin
mab predomin global market
mab clinic trial china
mab still earli age china
yet
sale estim livzon mab china
incid
note price local mab assum humira negoti price
cancer statist china huatai hk research
potenti blockbust way
use treatment dlbcl fl cll patent drug rituxan contribut
global sale revenu share mab market
note asia higher proport peopl suffer dlbcl nhl
patient indic bigger pool potenti patient three produc
enter phase clinic trial anticip livzon grab market share
annual sale revenu given high qualiti standard biosimilar
mab sale global lead drug
nhl sub-typ asia
mab clinic trial china
note indic drug nda
sale estim livzon mab china
treatment malign lymphoma huatai hk research
yet
incid
note nhl incid china dlbcl fl cll
note price local mab assum rituximab negoti price
cancer statist china huatai hk research
tnf- catch first armi
humira adalimumab world best-sel drug past five year
global sale situat quit differ china
humira see sluggish sale judg sampl hospit
partial due high out-of-pocket spend pa weak
willing undergo treatment
fc-fusion protein domin local market launch three domest
three five domest mab expect next three year four phase
assum medicin rate patient pa averag
cost project livzon reach peak sale market share
anti-tnf- mab sale global lead drug
anti-tnf- mab sale lead drug china
anti-tnf- mab clinic trial china
yet on-going
note mean drug undergon bioequival test
sale estim livzon anti-tnf- mab china
note price local anti-tnf- mab assum half humira set averag month treatment per year
microspher degrad polym matrix contain drug molecul extend
releas particularli favor patient mental disord
poor adher medic requir hormon treatment need stabl plasma
concentr suffer diabet chronic diseas
livzon domest leader microspher platform global
microspher drug develop includ blockbust risperd consta
johnson johnson sale china five domest
player space two product market leuprolid livzon
biot present livzon product develop
triptorelin phase manag guid first drug expect
make debut view microspher growth driver make
microspher technolog still nascent china
note estim year launch rank refer domest product
aripiprazol microspher new star schizophrenia market
 achiev enviabl success anti-schizophrenia drug market
consolid lead global posit pipelin renov first gener
risperidon regular form achiev sale revenu
replac long-act altern risperd consta bi-weekli reach peak sale
sinc surpass invega sustenna monthli
continu ramp
 js strateg develop long-act drug
long-act drug futur trend view see inevit trend long-
act replac given better complianc pain point schizophrenia patient
higher econom effici poor complianc may lead higher care cost
relaps rate among four long-act product market new gener
paliperidon aripiprazol rapidli take market share
long-act schizophrenia rx drug us
livzon aripiprazol microspher see market size consid
rel low penetr long-act schizophrenia drug china versu
us larg unmet clinic demand given larg patient pool
schizophrenia patient bipolar-disord patient livzon like
benefit one first mover space
atyp schizophrenia drug china
growth lead schizophrenia drug china
note target approv clinic trial qilu risperidon haosen paliperidon kelun aripiprazol
sale estim livzon long-act schizophrenia drug china
guidelin biolog treatment schizophrenia huatai hk research
hormone-rel drug cover full spectrum long-act drug
develop long-act formul spawn three relin eg leuprorelin
triptorelin goserelin use sex hormone-rel tumor eg prostat
cancer breast cancer hysteromyoma endometriosi children precoci
puberti cpp livzon three hormone-rel drug leuprorelin triptorelin
goserelin
leuprorelin product local supplier china market livzon
biot see fast import substitut area market share mainli
attribut lower cost price cut versu patent drug advantag
local promot market leader anticip livzon enhanc edg
next three-month sustain releas product slate launch
leuprorelin microspher competit landscap china
approv clinic trial
appli clinic trial
note price deriv averag tender price jiangsu shanghai jilin guizhou hubei guangdong
triptorelin patent drug look like see slower growth global domest
market howev believ local product growth engin due price
elast import substitut livzon demonstr lead posit
decent pipelin includ one-month microspher await approv ind
three-month microspher pre-clin pilot batch
triptorelin microspher competit landscap china
approv clinic trial
approv clinic trial
approv clinic trial
note price deriv averag tender price jiangsu shanghai jilin liaon sichuan
goserelin shift formul implant consider clinic
valid seemingli higher success rate follow patent drug acceler
progress clinic trial robust growth goserelin patent drug china
yoy
goserelin sustained-releas competit landscap china
note price deriv averag tender price jiangsu shanghai jilin guizhou hubei shanxi
see potenti market livzon hormone-rel long-act
drug given relin gener aggreg global sale revenu
though around china grow ivf demand driven later childbear
plu two-child polici larg unaddress market cpp less livzon
uniqu strength sale network
sale estim livzon hormone-rel long-act drug china
note incid china pc male correspond asr bc femal around menopaus period correspond
asr endometriosi femal childbear age age correspond asr assum plan babi current year
cpp adolesc age correspond asr
cancer statist china guidelin treatment endometriosi huatai hk research
financi forecast valuat
growth predict ep compound-annual-growth-rate
cornerston ep compound-annual-growth-rate forecast
ilaprazol inject approv product estim
combin sale revenu compound-annual-growth-rate project develop
market next five year
leuprorelin sustain strong growth momentum project
sale revenu compound-annual-growth-rate
adjuv drug shenqi fuzheng inject contribut stabl profit ngf
maintain moder growth annual re-entri
guangdong market exit earlier
area multipl blockbust slate launch
urofollitropin inject
net profit attribut parent
project continu stabl growth sg cost mainli attribut abund cash
flow hand due land dispos streamlin pipelin riski
expens time-consum project cut cost shenqi
fuzheng grassroot expans control
assumpt key expens
revenu
revenu
initi buy target price
livzon growth deriv view rapid growth drug segment
decent pipelin number blockbust mab microspher
platform pipelin expans oversea busi develop
forecast livzon organ net profit compound-annual-growth-rate rmb basi revenu
compound-annual-growth-rate predict ep
correspond pe target price base pe
averag h-share peer impli share upsid initi coverag
risk view
identifi follow downsid risk earn forecast buy rate
slower-than-expect progress ilaprazol inject tender
faster-than-expect declin shenqi fuzheng due adjuv restrict
delay new launch unqualifi clinic result
list abbrevi use report
intern council harmonis
receptor activ nuclear factor- ligand
tegafur gimeracil oteracil porassium
livzon devot busi expans sinc build success shenqi
fuzheng inject livzon strengthen sale chemic prepar
segment includ patent varieti exclus varieti past five year
livzon expand area genet test precis medicin
livzon establish januari boast clear ownership structur regist
capit list a- h-share stock market
jointcar becam control sharehold livzon hold share
net profit attribut parent compani
livzon gm segment
api intermedi
diagnost reagent equip
asset liabil ratio rh
livzon margin sg
sell distribut expens
flow oper
flow invest
flow financ activ
cash equival end period
incom statementy dec good distrib oper rmb sheety dec bill cash current current long-term long-term current long-term long-term rmb dec yield yield flow statementy dec work cash invest cash financ cash start fx rate ratio gross net gear ratio capabl day total asset t/o ratio convers livzon pharma hk
view express report accur reflect person view analyst subject secur suer part
compens analyst directli indirectli relat inclus specif recommend view
